Format

Send to

Choose Destination
Prescrire Int. 2012 Jun;21(128):150.

Drugs for Alzheimer's disease: best avoided. No therapeutic advantage.

[No authors listed]

Abstract

The French Pharmacoeconomic Committee that assesses the medical benefit of new drugs and provides recommendations about reimbursement has downgraded its rating of the medical benefit (SMR, service mddical rendu) provided by cholinesterase inhibitors and memantine in Alzheimer's disease from "major" to "low".

PMID:
22822592
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center